Abstract: The present technology relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, devices are designed to be portable, wearable, disposable and self-contained extracorporeal devices that can be easily assembled from a kit.

Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Abstract: Methods for preparing functionalized polyvinylpyrrolidones with polymerizable functions. Also, amphipathic polydimethylsiloxane-PVP block copolymers, such as and (meth)acrylated and (meth)acrylamide-functionalized polyvinylpyrrolidone compounds, such as The block copolymers are useful as biomaterial components in biomedical devices. They provide improved wettability, lubricity, and material compatibility to the biomedical device, e.g., ophthalmic lenses.

Abstract: Polymers having the formula R(LE)X wherein R is a polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons and x endgroups, E is an endgroup that is covalently linked to polymeric core R by linkage L, L is a divalent oligomeric chain having at least 5 identical repeat units that is capable of self-assembly with L chains on adjacent molecules of the polymer, and the moieties (LE)X in the polymer may be the same as or different from one another. Monomers, oligomers, or other reactive structures otherwise analogous to known Self Assembled Monolayers but with at least one reactive chemical group capable of binding them to the terminus of a polymer, so that the thiol-free SAM analogue becomes the self-assembling surface modifying endgroup of that polymer, may be designed. Use of the polymer to fabricate a configured article from the surface-modified polymer or to fabricate a coating or topical treatment on an article made from another material.

Abstract: Methods for preparing functionalized polyvinylpyrrolidones with polymerizable functions. Also, amphipathic polydimethylsiloxane-PVP block copolymers, such as and (meth)acrylated and (meth)acrylamide-functionalized polyvinylpyrrolidone compounds, such as The block copolymers are useful as biomaterial components in biomedical devices. They provide improved wettability, lubricity, and material compatibility to the biomedical device, e.g., ophthalmic lenses.

Abstract: Methods for preparing functionalized polyvinylpyrrolidones with polymerizable functions. Also, amphipathic polydimethylsiloxane-PVP block copolymers, such as and (meth)acrylated and (meth)acrylamide-functionalized polyvinylpyrrolidone compounds, such as The block copolymers are useful as biomaterial components in biomedical devices. They provide improved wettability, lubricity, and material compatibility to the biomedical device, e.g., ophthalmic lenses.

Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Abstract: A silicone hydrogel formulation may contains random and/or block copolymers or oligomers or macromers. The silicone copolymer is copolymerized or blended with other polymers or monomers or macromers to obtain final formulation. The silicone hydrogel may contain crosslinking groups to provide a complete or partially crosslinked final structure. The silicone hydrogel formulation may be pre-formed as a film or other structure, or it may be polymerized during application as in the case of an adhesive formulation. A wound dressing comprising a silicone hydrogel formed as a film, either prior to application to a wound or in situ on a wound, which film has gas permeability, moisture permeability, and high water content, wherein said silicone hydrogel is formed from a polymerizable silicone such as a difunctional polydimethylsiloxane methacrylate and crosslinking agents such as N,N-dimethyllacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), and trimethylsiloxy silane (TRIS).

Abstract: Polymers whose surfaces are modified by endgroups that include amphipathic surface-modifying moieties. An amphipathic endgroup of a polymer molecule is an endgroup that contains at least two moieties of significantly differing composition, such that the amphipathic endgroup spontaneously rearranges its positioning in a polymer body to position the moiety on the surface of the body, depending upon the composition of the medium with which the body is in contact, when that re-positioning causes a reduction in interfacial energy. An example of an amphipathic surface-modifying endgroup is one that has both a hydrophobic moiety and a hydrophilic moiety in a single endgroup. For instance, a hydrophilic poly(ethylene oxide) terminated with a hydrophilic hydroxyl group is not surface active in air when the surface-modifying endgroup is bonded to a more hydrophobic base polymer.

Abstract: Block copolymers are formulated with multifunctional chain extenders. The block copolymers include a soft segment and a hard segment made from a diisocyanate, an alkylene diamine chain extender, and a multifunctional chain extender which provides delayed crosslinking. The multifunctional chain extenders have a functionality and typically have at least one OH group. The multifunctional chain extenders may be aliphatic or aromatic triols or polyols, or may have other configurations, as described. The resulting block copolymers have improved mechanical properties such as compression set. They may be used in medical applications, or in industrial applications such as seal and gasket applications, including O-rings, window seals, and automotive gaskets. The initially-formed polyurethane resin behaves as a thermoplastic processable material, while the configured end-use product is thermoset.

Abstract: Polymers whose surfaces are modified by endgroups that include amphipathic surface-modifying moieties. An amphipathic endgroup of a polymer molecule is an endgroup that contains at least two moieties of significantly differing composition, such that the amphipathic endgroup spontaneously rearranges its positioning in a polymer body to position the moiety on the surface of the body, depending upon the composition of the medium with which the body is in contact, when that re-positioning causes a reduction in interfacial energy. An example of an amphipathic surface-modifying endgroup is one that has both a hydrophobic moiety and a hydrophilic moiety in a single endgroup. For instance, a hydrophilic poly(ethylene oxide) terminated with a hydrophilic hydroxyl group is not surface active in air when the surface-modifying endgroup is bonded to a more hydrophobic base polymer.

Abstract: Polymers whose surfaces are modified by endgroups that include amphipathic surface-modifying moieties. An amphipathic endgroup of a polymer molecule is an endgroup that contains at least two moieties of significantly differing composition, such that the amphipathic endgroup spontaneously rearranges its positioning in a polymer body to position the moiety on the surface of the body, depending upon the composition of the medium with which the body is in contact, when that re-positioning causes a reduction in interfacial energy. An example of an amphipathic surface-modifying endgroup is one that has both a hydrophobic moiety and a hydrophilic moiety in a single endgroup. For instance, a hydrophilic poly(ethylene oxide) terminated with a hydrophilic hydroxyl group is not surface active in air when the surface-modifying endgroup is bonded to a more hydrophobic base polymer.

Abstract: Polymers having the formula R(LE)x wherein R is a polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons and having x endgroups, E is an endgroup covalently linked to polymeric core R by linkage L, L is a divalent oligomeric chain, having at least 5 identical repeat units, capable of self-assembly with L chains on adjacent molecules of the polymer, and the moieties (LE)x in the polymer may be the same as or different from one another. Design of monomers, oligomers, or other reactive structures otherwise analogous to known Self Assembled Monolayers but with at least one reactive chemical group capable of binding them to the terminus of a polymer, so that the thiol-free SAM analogue becomes the self-assembling surface modifying endgroup of that polymer. Use of the polymer to fabricate a configured article from the surface-modified polymer or a coating or topical treatment on an article made from another material.